Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hartman ML et al. – Sirolimus appears to enhance the cytotoxicity of cisplatin in malignant pleural mesothelioma cell lines through the mammalian target of rapamycin pathway. These results provide a basis for the clinical evaluation of combined sirolimus and cisplatin chemotherapy in malignant pleural mesothelioma.

Related Articles

Late cutaneous metastases to the face from malignant pleural mesothelioma: A case report and review of the literature
World Journal of Surgical Oncology, 11/12/09    Relevance Score: 90%

Living with mesothelioma. A literature review
European Journal of Cancer Care, 10/27/09    Relevance Score: 87%

Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
American Journal of Surgical Pathology, 10/27/09    Relevance Score: 87%

Filing for workers' compensation among Ontario cases of mesothelioma
Canadian Respiratory Journal, 10/26/09    Relevance Score: 85%

Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
Lung Cancer, 10/01/09    Relevance Score: 85%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address